The initial compound to be formulated for Sustained Release using the Akina delivery technology will be for the treatment of Type II diabetes. Two additional types of drugs will be developed concurrently for use in prostate and breast cancer treatment and to provide tamper resistant pain management medicines.
We will be identifying additional pharmaceutical applications in phase 2 as part of the co-development and commercialization relationship between Akina and Sustained Release.